These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


60 related items for PubMed ID: 6707917

  • 1. Biological evaluation of some ionophore-polymeric chelator combinations for reducing iron overload.
    Tyson CA, LeValley SE, Chan R, Hobbs PD, Dawson MI.
    J Pharmacol Exp Ther; 1984 Mar; 228(3):676-81. PubMed ID: 6707917
    [Abstract] [Full Text] [Related]

  • 2. Improvement of iron removal from the reticuloendothelial system by liposome encapsulation of N,N'-bis[2-hydroxybenzyl]-ethylenediamine-N,N'-diacetic acid (HBED). Comparison with desferrioxamine.
    Lau EH, Cerny EA, Wright BJ, Rahman YE.
    J Lab Clin Med; 1983 May; 101(5):806-16. PubMed ID: 6403640
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of polymeric hydroxamic acid iron chelators for treatment of iron overload.
    Winston A, Varaprasad DV, Metterville JJ, Rosenkrantz H.
    J Pharmacol Exp Ther; 1985 Mar; 232(3):644-9. PubMed ID: 3973822
    [Abstract] [Full Text] [Related]

  • 4. Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311.
    Chaston TB, Lovejoy DB, Watts RN, Richardson DR.
    Clin Cancer Res; 2003 Jan; 9(1):402-14. PubMed ID: 12538494
    [Abstract] [Full Text] [Related]

  • 5. Hydrazone chelators for the treatment of iron overload disorders: iron coordination chemistry and biological activity.
    Bernhardt PV, Chin P, Sharpe PC, Richardson DR.
    Dalton Trans; 2007 Aug 14; (30):3232-44. PubMed ID: 17893768
    [Abstract] [Full Text] [Related]

  • 6. PCTH: a novel orally active chelator for the treatment of iron overload disease.
    Lovejoy DB, Kalinowski D, Bernhardt PV, Richardson DR.
    Hemoglobin; 2006 Aug 14; 30(1):93-104. PubMed ID: 16540421
    [Abstract] [Full Text] [Related]

  • 7. The development of new iron-chelating drugs. II.
    Grady RW, Graziano JH, White GP, Jacobs A, Cerami A.
    J Pharmacol Exp Ther; 1978 Jun 14; 205(3):575-65. PubMed ID: 660531
    [Abstract] [Full Text] [Related]

  • 8. Iron retention and excretion in mice transfused with homologous or heterologous blood and treated with chelators.
    Gralla EJ, Burgess DH.
    Methods Find Exp Clin Pharmacol; 1982 Jun 14; 4(3):151-9. PubMed ID: 7121126
    [Abstract] [Full Text] [Related]

  • 9. An in vivo evaluation of iron-chelating drugs derived from pyridoxal and its analogs.
    Johnson DK, Pippard MJ, Murphy TB, Rose NJ.
    J Pharmacol Exp Ther; 1982 May 14; 221(2):399-403. PubMed ID: 7077535
    [Abstract] [Full Text] [Related]

  • 10. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program .
    Natl Toxicol Program Tech Rep Ser; 1993 Sep 14; 422():1-340. PubMed ID: 12616289
    [Abstract] [Full Text] [Related]

  • 11. The iron metabolism of the human neuroblastoma cell: lack of relationship between the efficacy of iron chelation and the inhibition of DNA synthesis.
    Richardson DR, Ponka P.
    J Lab Clin Med; 1994 Nov 14; 124(5):660-71. PubMed ID: 7964124
    [Abstract] [Full Text] [Related]

  • 12. Iron absorption and hepatic iron uptake are increased in a transferrin receptor 2 (Y245X) mutant mouse model of hemochromatosis type 3.
    Drake SF, Morgan EH, Herbison CE, Delima R, Graham RM, Chua AC, Leedman PJ, Fleming RE, Bacon BR, Olynyk JK, Trinder D.
    Am J Physiol Gastrointest Liver Physiol; 2007 Jan 14; 292(1):G323-8. PubMed ID: 16935854
    [Abstract] [Full Text] [Related]

  • 13. NTP Toxicology and Carcinogenesis Studies of 4,4'-Thiobis(6- t -butyl- m -cresol) (CAS No. 96-69-5) in F344/N Rats and B6C3F1 Mice (Feed Studies).
    National Toxicology Program .
    Natl Toxicol Program Tech Rep Ser; 1994 Dec 14; 435():1-288. PubMed ID: 12595928
    [Abstract] [Full Text] [Related]

  • 14. Hemosiderosis in rodents and the effect of acetohydroxamic acid on urinary iron excretion.
    Corden BJ.
    Exp Hematol; 1986 Nov 14; 14(10):971-4. PubMed ID: 3770104
    [Abstract] [Full Text] [Related]

  • 15. Toxicology and Carcinogenesis Studies of 5,5-Diphenylhydantoin (CAS No. 57-41-0) (Phenytoin) in F344/N Rats and B6C3F1 Mice (Feed Studies).
    National Toxicology Program .
    Natl Toxicol Program Tech Rep Ser; 1993 Nov 14; 404():1-303. PubMed ID: 12621514
    [Abstract] [Full Text] [Related]

  • 16. Mechanism of in vivo iron chelation by pyridoxal isonicotinoyl hydrazone and other imino derivatives of pyridoxal.
    Hershko C, Avramovici-Grisaru S, Link G, Gelfand L, Sarel S.
    J Lab Clin Med; 1981 Jul 14; 98(1):99-108. PubMed ID: 7252329
    [Abstract] [Full Text] [Related]

  • 17. Future of toxicology--iron chelators and differing modes of action and toxicity: the changing face of iron chelation therapy.
    Kalinowski DS, Richardson DR.
    Chem Res Toxicol; 2007 May 14; 20(5):715-20. PubMed ID: 17402750
    [Abstract] [Full Text] [Related]

  • 18. The treatment of animal models of malaria with iron chelators by use of a novel polymeric device for slow drug release.
    Golenser J, Domb A, Teomim D, Tsafack A, Nisim O, Ponka P, Eling W, Cabantchik ZI.
    J Pharmacol Exp Ther; 1997 Jun 14; 281(3):1127-35. PubMed ID: 9190845
    [Abstract] [Full Text] [Related]

  • 19. A new approach for potential combined chelation therapy using mono- and bis-hydroxypyridinones.
    Santos MA, Gama S, Gil M, Gano L.
    Hemoglobin; 2008 Jun 14; 32(1-2):147-56. PubMed ID: 18274992
    [Abstract] [Full Text] [Related]

  • 20. Combination of iron overload plus ethanol and ischemia alone give rise to the same endogenous free iron pool.
    Sergent O, Tomasi A, Ceccarelli D, Masini A, Nohl H, Cillard P, Cillard J, Vladimirov YA, Kozlov AV.
    Biometals; 2005 Dec 14; 18(6):567-75. PubMed ID: 16388396
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 3.